In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Getting a Grip on Oncology Drug Costs--and Pricing

Executive Summary

Until now, the US oncology drug market has operated in its own economic universe. It's been a lucrative niche business, characterized by premium prices for drugs that address small, desperate patient populations, often coping with fatal diseases that lack effective therapies. The playing field, however, is changing rapidly, with multiple implications for manufacturers. Scientific progress-and money--are at the heart of the change. Changes in oncology reimbursement will affect pharmaceutical manufacturers' relationships with providers and payers as well as their development and commercialization strategies. v

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts